欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2024, Vol. 29 ›› Issue (5): 590-595.doi: 10.12092/j.issn.1009-2501.2024.05.015

• 综述与讲座 • 上一篇    下一篇

氧化三甲胺影响冠心病和抗血小板药物疗效的研究进展

彭园园,陈碧莲   

  1. 中南大学湘雅医院老年医学科,长沙  410078,湖南
  • 收稿日期:2024-01-15 修回日期:2024-03-10 出版日期:2024-05-26 发布日期:2024-04-16
  • 通讯作者: 陈碧莲,女,博士,主任医师,硕士生导师,研究方向:老年心血管疾病。 E-mail: 1281373573@qq.com
  • 作者简介:彭园园,女,医师,研究方向:老年心血管疾病。 E-mail: 1010891576@qq.com
  • 基金资助:
    湖南省科技厅科研课题(2022JJ70156);长沙市科技局科研课题(kq2202367)

Research progress of the effect of TMAO on coronary heart disease and the efficacy of antiplatelet drugs

PENG Yuanyuan, CHEN Bilian   

  1. Department of Geriatrics, Xiangya Hospital, Central South University, Changsha 410078, Hunan, China
  • Received:2024-01-15 Revised:2024-03-10 Online:2024-05-26 Published:2024-04-16

摘要:

冠心病目前仍是全球范围(包括中国)最常见的心血管疾病和死亡原因之一。抗血小板药物是治疗冠心病的基础性药物。近年来越来越多的研究发现,肠道菌群主要代谢产物氧化三甲胺(trimethylamine N-oxide,TMAO)可通过多种机制促进动脉粥样硬化,影响冠心病患者的预后和抗血小板药物的疗效。本文就这方面的研究进行综述。

关键词: 氧化三甲胺, 冠心病, 抗血小板药物

Abstract:

Coronary heart disease is still one of the most common cardiovascular disease and causes of death worldwide (including China). Antiplatelet drugs are fundamental in the treatment of coronary heart disease. In recent years, more and more studies have found that trimethylamine N-oxide (TMAO), a major metabolite of intestinal flora, can promote atherosclerosis through various mechanisms, affecting the prognosis of patients with coronary heart disease and the efficacy of antiplatelet drugs. This article reviews the effect of TMAO on coronary heart disease and the efficacy of antiplatelet drugs.

Key words: trimethylamine N-oxide, coronary heart disease, antiplatelet drug

中图分类号: